Special Issue

AI Technology and Precision Medicine in Neurodegenerative Diseases

Message from the Guest Editor

The field of artificial intelligence (AI) and precision medicine in neurodegenerative diseases is rapidly expanding, with the aim of enhancing the diagnosis, monitoring, and treatment of these conditions. Neurodegenerative dis-eases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease, present a significant challenge to modern medicine due to their intricate causes, progressive nature, and restricted treatment options.Artificial intelligence and precision medicine have significant potential in the fight against neurodegenerative diseases, offering new tools for better diagnosis, monitoring, and personalization of therapies. Despite these challenges, continued research and development of AI technologies can significantly contribute to improving the quality of life of patients and the efficiency of healthcare systems.Therefore, taking into consideration the significance of AI and precision medicine in neurodegenerative diseases, I would like to strongly encourage you to prepare a manuscript situated within this developing field of neurology.

Guest Editor

Dr. Stanisław Szlufik

Department of Neurology, Faculty of Health Science Medical, University of Warsaw, Warszawa, Poland

Deadline for manuscript submissions

25 November 2024

Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:
JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).